In Vitro and In Vivo Characterization of Tebipenem, an Orally Active Carbapenem, against Biothreat Pathogens-Reference-Cited by-同舟云学术

In Vitro and In Vivo Characterization of Tebipenem, an Orally Active Carbapenem, against Biothreat Pathogens

Published:2021-04-19 Issue:5 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Clayton Nicholas P.¹^ORCID,Jain Akash¹,Halasohoris Stephanie A.²,Pysz Lisa M.²,Lembirik Sanae²,Zumbrun Steven D.²,Kane Christopher D.²,Hackett Michael J.³,Pfefferle Denise³,Smiley M. Autumn³,Anderson Michael S.³,Heine Henry⁴,Meister Gabriel T.³,Pucci Michael J.¹

Affiliation:

1. Spero Therapeutics Inc., Cambridge, Massachusetts, USA

2. U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA

3. Battelle Memorial Institute, Columbus, Ohio, USA

4. Institute for Therapeutic Innovation, Department of Medicine, University of Florida, Orlando, Florida, USA

Abstract

Bacillus anthracis and Yersinia pestis , the causative pathogens for anthrax and plague, respectively, along with Burkholderia mallei and Burkholderia pseudomallei are potential bioterrorism threats. Tebipenem pivoxil hydrobromide (TBP HBr) (formerly SPR994) is an orally available prodrug of tebipenem, a carbapenem with activity versus multidrug-resistant (MDR) Gram-negative pathogens, including quinolone-resistant and extended-spectrum-β-lactamase-producing Enterobacterales .

Funder

DOD | Defense Threat Reduction Agency

HHS | Biomedical Advanced Research and Development Authority

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02385-20

Reference49 articles.

1. Forensic Odontology in the Management of Bioterrorism

2. Lessons to be learned from recent biosafety incidents in the United States;Weiss S;Isr Med Assoc J,2015

3. Public Health Assessment of Potential Biological Terrorism Agents

4. Centers for Disease Control and Prevention. 2018. Bioterrorism agents/diseases. Centers for Disease Control and Prevention, Atlanta, GA. https://emergency.cdc.gov/agent/agentlist-category.asp.

5. Clinical Management of Potential Bioterrorism-Related Conditions

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A ternary nucleotide–lanthanide coordination nanoprobe for ratiometric fluorescence detection of ciprofloxacin;Luminescence;2024-01-04

2. Efficacy of ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)) in rabbit and nonhuman primate models of inhalational anthrax: Data supporting approval under animal rule;PLOS ONE;2023-03-17

3. Efficacy of delafloxacin against the biothreat pathogenBacillus anthracis;Journal of Antimicrobial Chemotherapy;2023-02-04

4. β-Lactam antibiotics;Medicinal Chemistry of Chemotherapeutic Agents;2023

5. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection;Antimicrobial Agents and Chemotherapy;2022-11-15